M Radin1, K Schreiber2, P Costanzo3, I Cecchi1, D Roccatello1, S Baldovino1, M Bazzan4, M J Cuadrado5, S Sciascia6. 1. Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy. 2. Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom; Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark. 3. Cardiology Departiment, S. Giovanni Bosco Hospital, Turin, Italy. 4. UOSD Hematology and Thrombosis Unit, S. Giovanni Bosco Hospital, Turin, Italy. 5. Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK. 6. Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy. Electronic address: savino.sciascia@unito.it.
Abstract
BACKGROUND: Young adults with acute myocardial infarction are a critical group to examine for the purpose of risk factor stratification and modification. In this study we aimed to assess the clinical utility of the adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for the risk stratification of acute myocardial infarction in a cohort of young patients with antiphospholipid syndrome (APS). METHODS: The analysis included 83 consecutive APS patients (≤50years old) who presented with arterial or venous thromboembolic events. Data on cardiovascular risk factors and antiphospholipid antibodies (aPL) positivity were retrospectively collected. The aGAPSS was calculated by adding the points corresponding to the risk factors, based on a linear transformation derived from the ß-regression coefficient as follows: 3 for hyperlipidaemia, 1 for arterial hypertension, 5 for aCL IgG/IgM, 4 for anti-b2 glycoprotein I IgG/IgM and 4 for LA. RESULTS: Higher aGAPSS values were observed in patients with acute myocardial infarction when compared to the others [mean aGAPSS 11.9 (S.D. 4.15, range 4-18) Vs. mean aGAPSS 9.2 (S.D. 5.1, range 1-17); T test: p<0.05]. Significantly higher aGAPSS values were also seen in patients with acute coronary syndrome compared to patients with a history of peripheral or cerebrovascular arterial thrombotic events [mean aGAPSS 11.9 (S.D. 4.15, range 4-18) Vs. mean aGAPSS 6.7 (S.D. 5.7, range 1-17); T test: P<0.005]. CONCLUSIONS: The aGAPSS is based upon a quantitative score and could aid risk stratifying APS patients younger than 50years for the likelihood of developing coronary thrombotic events and may guide pharmacological treatment for high-risk patients.
BACKGROUND: Young adults with acute myocardial infarction are a critical group to examine for the purpose of risk factor stratification and modification. In this study we aimed to assess the clinical utility of the adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for the risk stratification of acute myocardial infarction in a cohort of young patients with antiphospholipid syndrome (APS). METHODS: The analysis included 83 consecutive APSpatients (≤50years old) who presented with arterial or venous thromboembolic events. Data on cardiovascular risk factors and antiphospholipid antibodies (aPL) positivity were retrospectively collected. The aGAPSS was calculated by adding the points corresponding to the risk factors, based on a linear transformation derived from the ß-regression coefficient as follows: 3 for hyperlipidaemia, 1 for arterial hypertension, 5 for aCL IgG/IgM, 4 for anti-b2 glycoprotein I IgG/IgM and 4 for LA. RESULTS: Higher aGAPSS values were observed in patients with acute myocardial infarction when compared to the others [mean aGAPSS 11.9 (S.D. 4.15, range 4-18) Vs. mean aGAPSS 9.2 (S.D. 5.1, range 1-17); T test: p<0.05]. Significantly higher aGAPSS values were also seen in patients with acute coronary syndrome compared to patients with a history of peripheral or cerebrovascular arterial thrombotic events [mean aGAPSS 11.9 (S.D. 4.15, range 4-18) Vs. mean aGAPSS 6.7 (S.D. 5.7, range 1-17); T test: P<0.005]. CONCLUSIONS: The aGAPSS is based upon a quantitative score and could aid risk stratifying APSpatients younger than 50years for the likelihood of developing coronary thrombotic events and may guide pharmacological treatment for high-risk patients.
Authors: Massimo Radin; Savino Sciascia; Doruk Erkan; Vittorio Pengo; Maria G Tektonidou; Amaia Ugarte; Pierluigi Meroni; Lanlan Ji; H Michael Belmont; Hannah Cohen; Guilherme Ramires de Jesús; D Ware Branch; Paul R Fortin; Laura Andreoli; Michelle Petri; Esther Rodriguez; Ignasi Rodriguez-Pinto; Jason S Knight; Tatsuya Atsumi; Rohan Willis; Emilio Gonzalez; Rosario Lopez-Pedrera; Ana Paula Rossi Gandara; Margarete Borges Gualhardo Vendramini; Alessandra Banzato; Ecem Sevim; Medha Barbhaiya; Maria Efthymiou; Ian Mackie; Maria Laura Bertolaccini; Danieli Andrade Journal: Semin Arthritis Rheum Date: 2019-05-02 Impact factor: 5.532
Authors: Flavio Signorelli; Gustavo Guimarães Moreira Balbi; Nadia E Aikawa; Clovis A Silva; Léonard de Vinci Kanda Kupa; Ana C Medeiros-Ribeiro; Emily Fn Yuki; Sandra G Pasoto; Carla Gs Saad; Eduardo F Borba; Luciana Parente Costa Seguro; Tatiana Pedrosa; Vitor Antonio de Angeli Oliveira; Ana Luisa Cerqueira de Sant'Ana Costa; Carolina T Ribeiro; Roseli Eliana Beseggio Santos; Danieli Castro Oliveira Andrade; Eloisa Bonfá Journal: Lupus Date: 2022-05-20 Impact factor: 2.858
Authors: Savino Sciascia; Irene Cecchi; Massimo Radin; Elena Rubini; Ana Suárez; Dario Roccatello; Javier Rodríguez-Carrio Journal: Front Med (Lausanne) Date: 2019-09-26
Authors: Sara Del Barrio-Longarela; Víctor M Martínez-Taboada; Pedro Blanco-Olavarri; Ana Merino; Leyre Riancho-Zarrabeitia; Alejandra Comins-Boo; Marcos López-Hoyos; José L Hernández Journal: Clin Rev Allergy Immunol Date: 2021-12-15 Impact factor: 10.817
Authors: G R de Jesús; S Sciascia; D Andrade; M Barbhaiya; M Tektonidou; A Banzato; V Pengo; L Ji; P L Meroni; A Ugarte; H Cohen; D W Branch; L Andreoli; H M Belmont; P R Fortin; M Petri; E Rodriguez; R Cervera; J S Knight; T Atsumi; R Willis; I S Nascimento; R Rosa; D Erkan; R A Levy Journal: BJOG Date: 2018-10-24 Impact factor: 6.531
Authors: Hannah Cohen; Maria J Cuadrado; Doruk Erkan; Ali Duarte-Garcia; David A Isenberg; Jason S Knight; Thomas L Ortel; Anisur Rahman; Jane E Salmon; Maria G Tektonidou; David J Williams; Rohan Willis; Scott C Woller; Danieli Andrade Journal: Lupus Date: 2020-10 Impact factor: 2.911